[Incheon] RudaCure, a drug discovery company targeting membrane proteins and ion channels, will present Phase 1 clinical results for its dry eye disease candidate RCI001/HL262 in a poster at the 2026 Annual Meeting of the American College of Clinical Pharmacology (ACCP), held September 27 to 29 in North Bethesda, Maryland, USA.
The poster is titled "Safety, tolerability, and pharmacokinetics of RCI001/HL262 after single and multiple ophthalmic administrations." It reports the first-in-human evaluation of safety, tolerability and pharmacokinetics of RCI001/HL262 0.25% eye drops following single and multiple administrations in healthy adults.
The presentation is delivered by the Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital. Yejin Cho is the first author, with Yoonjin Kim, Hyun Chul Kim, Kyung-Sang Yu and SeungHwan Lee as co-authors. The study was sponsored by RudaCure.
RCI001/HL262 is an ophthalmic formulation whose active ingredient is 8-oxo-2'-deoxyguanosine, a molecule that occurs endogenously. Nonclinical work has reported anti-inflammatory activity through inhibition of Rac1 (Ras-related C3 botulinum toxin substrate 1), a small GTPase that regulates inflammatory responses and reactive oxygen species production.
The poster
About the meeting
The American College of Clinical Pharmacology brings together clinical pharmacology groups from pharmaceutical companies, regulatory reviewers, modeling and simulation scientists, and academia. It publishes The Journal of Clinical Pharmacology and Clinical Pharmacology in Drug Development.
The 2026 Annual Meeting runs September 27 to 29 at the Bethesda North Marriott Hotel & Conference Center. Poster sessions take place on Sunday September 27 and Monday September 28, from 5:00 to 7:00 PM in Grand Ballroom E-H, with presenting authors at their boards during the first hour of each session.
RudaCure welcomes researchers and industry colleagues to stop by the poster. The poster number will be posted onsite.
The announcement is also posted on the RudaCure LinkedIn page. View the LinkedIn post